Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions, announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The event is scheduled for June 15-16, 2026, and the fireside chat will be available on demand starting June 15 at 7:00 a.m. EDT.
Helus Pharma, the commercial operating name of Cybin Inc., is dedicated to addressing the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions. The company’s proprietary NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, offering potential durable improvements in mental health.
The company is currently advancing two key candidates: HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration; and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma maintains an extensive research portfolio of investigational NSAs.
The participation of the Chief Medical Officer at this conference underscores the company’s commitment to advancing its pipeline and engaging with the investment community. For leaders in business and technology, this news highlights the growing convergence of biotechnology and neuroscience, with potential implications for the treatment of mental health disorders that affect millions worldwide. The development of novel therapies like HLP003 and HLP004 could reshape the treatment landscape, offering new options for patients who do not respond adequately to existing treatments.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more information about the company and its pipeline, visit www.helus.com. The full press release regarding this announcement is available at https://ibn.fm/KsnJW.
This news matters because it provides insight into the progress of clinical-stage companies that are leveraging cutting-edge science to address critical mental health needs. For investors and industry observers, the conference presentation offers an opportunity to hear directly from company leadership about the potential of NSAs and the status of clinical trials. The Breakthrough Therapy Designation for HLP003 signals FDA recognition of the potential for this therapy to offer significant improvement over existing options, which could accelerate its development and review process.
As mental health continues to be a global priority, the work of companies like Helus Pharma may have far-reaching impacts on patient outcomes and healthcare systems. The conference serves as a platform to highlight these advancements and their potential to transform the standard of care.
